Effects of canakinumab on lipid levels and inflammatory biomarkers in diabetics: a dose-ranging study

Trial Profile

Effects of canakinumab on lipid levels and inflammatory biomarkers in diabetics: a dose-ranging study

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2012

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Cardiovascular disorders; Diabetes mellitus
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 24 Apr 2012 New trial record
    • 27 Mar 2012 Results presented at the 61st Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top